Rituximab treatment of blistering disease

Treatment of refractory autoimmuno blistering disease with rituximab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180220

Enrollment

Registered

2019-03-15

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid

Interventions

Infusion of rituximab (1000mg) intravenously. Approximately two weeks after the first dose, a second dose of rituximab is administered in a similar manner.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed with pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid, with sufficient explanation and obtained research consent as sentences.

Exclusion criteria

Exclusion criteria: Patients diagnosed as inappropriate by the judgment of the doctor.

Design outcomes

Primary

Measure	Time frame
Reduction of immunosuppressive agent and steroid dose.	—

Secondary

Measure	Time frame
Improvement of clinical symptoms, reduction of antibody titer.	—

Contacts

Public ContactMiwa Kanaoka

Yokohama City University Hospital

kanaokam@yokohama-cu.ac.jp+81-45-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026